Increasing Focus on Transcatheter Mitral Valve Replacement

According to a new research report by RNCOS entitled, ?Global Transcatheter Market Outlook 2020?, efforts are now being focused on the development of another structural heart procedure: transcatheter mitral valve replacement (TMVR).

With the efficacy of transcatheter aortic valve replacement, firmly established, there is an increased focus on the treatment of mitral valve disease.

The year 2015, witnessed some major, acquisitions; all aimed at the further development for the TMVR procedures. For instance, Edwards Lifesciences Corporation acquired CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system. Similarly, Medtronic plc signed a definitive agreement to acquire Twelve, Inc., a privately-held medical device company focused on the development of a transcatheter mitral valve replacement (TMVR) device. Following the trend, Abbott Laboratories also completed the acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Tendyne's Bioprosthetic Mitral Valve System is designed to be implanted in a beating heart, without the need for open heart surgery, which would be a new treatment option for mitral valve replacement.

Major player like Edward Lifesciences, with their FORTIS trial, which involves the development of transcatheter mitral valve, is all ready to enter the market. Neovasc Inc. received an approval by the US FDA for the participating physicians to treat patients with its 40mm Tiara? valve in the Company's TIARA-I Early Feasibility Trial. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial to assess the safety and performance of Neovasc's Tiara? Mitral Valve System and implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation. Mitral valve disease is highly complex and requires multiple treatment options in order to tailor the therapy based on each person?s anatomy and health situation. This increased focus on TMVR will further lead to increase in the overall market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM816.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm


ABOUT RNCOS


RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Company :-RNCOS E-Services Pvt. Ltd.

User :- Shushmul Maheshwari

Email :-press@rncos.com

Phone :-24700-24700-04224700

Mobile:- 24700-1204224700

Url :- http://www.rncos.com